LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 327

Suchoptionen

  1. Buch: Non-alcoholic steatohepatitis

    Sarkar, Devanand

    methods and protocols

    (Methods in molecular biology ; 2455 ; Springer protocols)

    2022  

    Verfasserangabe edited by Devanand Sarkar
    Serientitel Methods in molecular biology ; 2455
    Springer protocols
    Überordnung
    Schlagwörter Fatty liver ; Liver/Diseases/Molecular aspects
    Thema/Rubrik (Code) 616.362
    Sprache Englisch
    Umfang xiii, 361 Seiten, Illustrationen, Diagramme, 26 cm
    Verlag Humana Press
    Erscheinungsort New York, NY
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch
    HBZ-ID HT021275607
    ISBN 978-1-0716-2127-1 ; 9781071621288 ; 1-0716-2127-0 ; 1071621289
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  2. Buch: Mechanisms and therapy of liver cancer

    Sarkar, Devanand

    (Advances in cancer research ; volume 149)

    2021  

    Verfasserangabe edited by Devanand Sarkar, Paul B. Fisher
    Serientitel Advances in cancer research ; volume 149
    Überordnung
    Sprache Englisch
    Umfang xiii, 387 Seiten, Illustrationen
    Ausgabenhinweis First edition
    Verlag Elsevier AP
    Erscheinungsort Cambridge, MA
    Erscheinungsland Niederlande
    Dokumenttyp Buch
    HBZ-ID HT020862909
    ISBN 978-0-12-824030-4 ; 0-12-824030-X
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  3. Buch: AEG-1 MTDH LYRIC implicated in multiple human cancers

    Sarkar, Devanand

    (Advances in cancer research ; 120)

    2013  

    Verfasserangabe ed. by Devanand Sarkar
    Serientitel Advances in cancer research ; 120
    Überordnung
    Sprache Englisch
    Umfang XIV, 232 S. : Ill.
    Ausgabenhinweis 1. ed.
    Verlag Elsevier
    Erscheinungsort Amsterdam u.a.
    Erscheinungsland Niederlande
    Dokumenttyp Buch
    HBZ-ID HT017821789
    ISBN 978-0-12-401676-7 ; 0-12-401676-6
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  4. Artikel: Providing meaningful survival benefit to hepatocellular carcinoma patients: combination therapy of future.

    Sarkar, Devanand

    Hepatobiliary surgery and nutrition

    2022  Band 11, Heft 5, Seite(n) 779–781

    Sprache Englisch
    Erscheinungsdatum 2022-10-06
    Erscheinungsland China (Republic : 1949- )
    Dokumenttyp Editorial ; Comment
    ZDB-ID 2812398-0
    ISSN 2304-389X ; 2304-3881
    ISSN (online) 2304-389X
    ISSN 2304-3881
    DOI 10.21037/hbsn-22-322
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: HCC-Related lncRNAs

    Mimansha Shah / Devanand Sarkar

    International Journal of Molecular Sciences, Vol 25, Iss 1, p

    Roles and Mechanisms

    2024  Band 597

    Abstract: Hepatocellular carcinoma (HCC) presents a significant global health threat, particularly in regions endemic to hepatitis B and C viruses, and because of the ongoing pandemic of obesity causing metabolic-dysfunction-related fatty liver disease (MAFLD), a ... ...

    Abstract Hepatocellular carcinoma (HCC) presents a significant global health threat, particularly in regions endemic to hepatitis B and C viruses, and because of the ongoing pandemic of obesity causing metabolic-dysfunction-related fatty liver disease (MAFLD), a precursor to HCC. The molecular intricacies of HCC, genetic and epigenetic alterations, and dysregulated signaling pathways facilitate personalized treatment strategies based on molecular profiling. Epigenetic regulation, encompassing DNA methyltion, histone modifications, and noncoding RNAs, functions as a critical layer influencing HCC development. Long noncoding RNAs (lncRNAs) are spotlighted for their diverse roles in gene regulation and their potential as diagnostic and therapeutic tools in cancer. In this review, we explore the pivotal role of lncRNAs in HCC, including MAFLD and viral hepatitis, the most prevalent risk factors for hepatocarcinogenesis. The dysregulation of lncRNAs is implicated in HCC progression by modulating chromatin regulation and transcription, sponging miRNAs, and influencing structural functions. The ongoing studies on lncRNAs contribute to a deeper comprehension of HCC pathogenesis and offer promising routes for precision medicine, highlighting the utility of lncRNAs as early biomarkers, prognostic indicators, and therapeutic targets.
    Schlagwörter hepatocellular carcinoma ; long noncoding RNA ; prognosis ; treatment ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Thema/Rubrik (Code) 610
    Sprache Englisch
    Erscheinungsdatum 2024-01-01T00:00:00Z
    Verlag MDPI AG
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: HCC-Related lncRNAs: Roles and Mechanisms.

    Shah, Mimansha / Sarkar, Devanand

    International journal of molecular sciences

    2024  Band 25, Heft 1

    Abstract: Hepatocellular carcinoma (HCC) presents a significant global health threat, particularly in regions endemic to hepatitis B and C viruses, and because of the ongoing pandemic of obesity causing metabolic-dysfunction-related fatty liver disease (MAFLD), a ... ...

    Abstract Hepatocellular carcinoma (HCC) presents a significant global health threat, particularly in regions endemic to hepatitis B and C viruses, and because of the ongoing pandemic of obesity causing metabolic-dysfunction-related fatty liver disease (MAFLD), a precursor to HCC. The molecular intricacies of HCC, genetic and epigenetic alterations, and dysregulated signaling pathways facilitate personalized treatment strategies based on molecular profiling. Epigenetic regulation, encompassing DNA methyltion, histone modifications, and noncoding RNAs, functions as a critical layer influencing HCC development. Long noncoding RNAs (lncRNAs) are spotlighted for their diverse roles in gene regulation and their potential as diagnostic and therapeutic tools in cancer. In this review, we explore the pivotal role of lncRNAs in HCC, including MAFLD and viral hepatitis, the most prevalent risk factors for hepatocarcinogenesis. The dysregulation of lncRNAs is implicated in HCC progression by modulating chromatin regulation and transcription, sponging miRNAs, and influencing structural functions. The ongoing studies on lncRNAs contribute to a deeper comprehension of HCC pathogenesis and offer promising routes for precision medicine, highlighting the utility of lncRNAs as early biomarkers, prognostic indicators, and therapeutic targets.
    Mesh-Begriff(e) Humans ; Carcinoma, Hepatocellular/genetics ; RNA, Long Noncoding/genetics ; Epigenesis, Genetic ; Liver Neoplasms/genetics ; Bandages
    Chemische Substanzen RNA, Long Noncoding
    Sprache Englisch
    Erscheinungsdatum 2024-01-02
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms25010597
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Preface.

    Sarkar, Devanand / Fisher, Paul B

    Advances in cancer research

    2021  Band 149, Seite(n) xi–xiii

    Mesh-Begriff(e) Animals ; Carcinoma, Hepatocellular/diagnosis ; Carcinoma, Hepatocellular/therapy ; Combined Modality Therapy ; Humans ; Liver Neoplasms/diagnosis ; Liver Neoplasms/therapy
    Sprache Englisch
    Erscheinungsdatum 2021-02-10
    Erscheinungsland United States
    Dokumenttyp Editorial
    ZDB-ID 127-2
    ISSN 2162-5557 ; 0065-230X
    ISSN (online) 2162-5557
    ISSN 0065-230X
    DOI 10.1016/S0065-230X(21)00015-4
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Statins as Inhibitors of Lung Cancer Bone Metastasis

    Devanand Sarkar

    EBioMedicine, Vol 19, Iss C, Pp 6-

    2017  Band 7

    Schlagwörter Medicine ; R ; Medicine (General) ; R5-920
    Sprache Englisch
    Erscheinungsdatum 2017-05-01T00:00:00Z
    Verlag Elsevier
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  9. Artikel: Emerging Therapies for Hepatocellular Carcinoma (HCC).

    Chakraborty, Eesha / Sarkar, Devanand

    Cancers

    2022  Band 14, Heft 11

    Abstract: Hepatocellular carcinoma (HCC) arises from hepatocytes and accounts for 90% of primary liver cancer. According to Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2020, globally HCC is the sixth most common cancer and the third most common ... ...

    Abstract Hepatocellular carcinoma (HCC) arises from hepatocytes and accounts for 90% of primary liver cancer. According to Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2020, globally HCC is the sixth most common cancer and the third most common cause of cancer-related deaths. Reasons for HCC prognosis remaining dismal are that HCC is asymptomatic in its early stages, leading to late diagnosis, and it is markedly resistant to conventional chemo- and radiotherapy. Liver transplantation is the treatment of choice in early stages, while surgical resection, radiofrequency ablation (RFA) and trans arterial chemoembolization (TACE) are Food and Drug Administration (FDA)-approved treatments for advanced HCC. Additional first line therapy for advanced HCC includes broad-spectrum tyrosine kinase inhibitors (TKIs), such as sorafenib and lenvatinib, as well as a combination of immunotherapy and anti-angiogenesis therapy, namely atezolizumab and bevacizumab. However, these strategies provide nominal extension in the survival curve, cause broad spectrum toxic side effects, and patients eventually develop therapy resistance. Some common mutations in HCC, such as in telomerase reverse transcriptase (
    Sprache Englisch
    Erscheinungsdatum 2022-06-04
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14112798
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel: Gene Screening for Prognosis of Non-Muscle-Invasive Bladder Carcinoma under Competing Risks Endpoints.

    Ke, Chenlu / Bandyopadhyay, Dipankar / Sarkar, Devanand

    Cancers

    2023  Band 15, Heft 2

    Abstract: Background: Discovering clinically useful molecular markers for predicting the survival of patients diagnosed with non−muscle-invasive bladder cancer can provide insights into cancer dynamics and improve treatment outcomes. However, the presence of ... ...

    Abstract Background: Discovering clinically useful molecular markers for predicting the survival of patients diagnosed with non−muscle-invasive bladder cancer can provide insights into cancer dynamics and improve treatment outcomes. However, the presence of competing risks (CR) endpoints complicates the estimation and inferential framework. There is also a lack of statistical analysis tools and software for coping with the high-throughput nature of these data, in terms of marker screening and selection. Aims: To propose a gene screening procedure for proportional subdistribution hazards regression under a CR framework, and illustrate its application in using molecular profiling to predict survival for non-muscle invasive bladder carcinoma. Methods: Tumors from 300 patients diagnosed with bladder cancer were analyzed for genomic abnormalities while controlling for clinically important covariates. Genes with expression patterns that were associated with survival were identified through a screening procedure based on proportional subdistribution hazards regression. A molecular predictor of risk was constructed and examined for prediction accuracy. Results: A six-gene signature was found to be a significant predictor associated with survival of non−muscle-invasive bladder cancer, subject to competing risks after adjusting for age, gender, reevaluated WHO grade, stage and BCG/MMC treatment (p-value < 0.001). Conclusion: The proposed gene screening procedure can be used to discover molecular determinants of survival for non−muscle-invasive bladder cancer and in general facilitate high-throughput competing risks data analysis with easy implementation.
    Sprache Englisch
    Erscheinungsdatum 2023-01-06
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15020379
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang